Suzhou Medilink Therapeutics Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Suzhou Medilink Therapeutics Ltd.
BioNTech Ramps Up Spending To Launch 10 Pivotal Cancer Studies In 2024
As COVID-19 vaccine sales decline, the company is investing billions in a diverse oncology pipeline including antibody drug conjugates, immunotherapy and cancer vaccines
BioNTech Is Aggressively Advancing ADCs
The company, which brought in four antibody-drug conjugates last year through dealmaking, outlined development plans for its Phase III candidate during a Q4 sales and earnings call.
BioNTech Eyes First Oncology Approvals By 2026
The biotech's CEO told the J.P. Morgan Healthcare Conference that the company aims to have multiple oncology products on the market by 2029, but it plans to retain a large presence in vaccines as well.
Roche Signs Up Medilink As China Biotech ADC Deal Spree Continues
The Swiss drug maker teams up with Chinese biotech Medilink to gain access to a preclinical c-Met-targeting antibody-drug conjugate and potential competitor to two frontrunners from AbbVie.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice